Skip to main content
. 2019 Jul 2;12(5):529–533. doi: 10.1111/cts.12648

Figure 1.

Figure 1

Consort flow diagram. ASM, acid suppressive medication. *Reasons for not meeting inclusion criteria were: patients who did not take at least one dose of pazopanib (n = 36), pazopanib indication not STS (n = 14), patients received pazopanib in the adjuvant setting (n = 4), patients received pazopanib for a clinical trial (n = 2), and patients followed locally by oncologist (n = 1). ASM, acid suppressive medication; STS, soft tissue sarcoma.